ArticleBlood advances2023

CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia.

Astrid Wintering et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.